There are 2949 resources available
1100P - Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma
Presenter: John Kirkwood
Session: E-Poster Display
Resources:
Abstract
1101P - Near real-time intraoperative melanoma diagnosis using deep neural networks
Presenter: Ruple Jairath
Session: E-Poster Display
Resources:
Abstract
1102P - Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study
Presenter: Paolo Ascierto
Session: E-Poster Display
Resources:
Abstract
1103P - Long-term survival of real-world advanced melanoma patients treated with targeted therapy
Presenter: Rawa Ismail
Session: E-Poster Display
Resources:
Abstract
1104P - Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
Presenter: Ralf Gutzmer
Session: E-Poster Display
Resources:
Abstract
1105P - Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial
Presenter: Peter Mohr
Session: E-Poster Display
Resources:
Abstract
1106P - International experience of ipilimumab and nivolumab in patients with advanced melanoma
Presenter: Patricio Serra-Bellver
Session: E-Poster Display
Resources:
Abstract
1107P - Clinical outcomes to checkpoint inhibitors in NRAS mutated metastatic melanoma (MM) compared with wild type BRAF/NRAS: An Italian Melanoma Intergroup (IMI) study
Presenter: Michele Guida
Session: E-Poster Display
Resources:
Abstract
1108P - Real world (RW) sequencing outcomes with immunotherapy and targeted therapy (TT) in BRAF+ metastatic melanoma (The NOBLE study series)
Presenter: Allison Warner
Session: E-Poster Display
Resources:
Abstract
1109P - Chinese subgroup results from an open-label, phase IIa study of dabrafenib plus trametinib in Asian patients with advanced BRAF V600-mutant melanoma (NCT02083354)
Presenter: Lili Mao
Session: E-Poster Display
Resources:
Abstract